Tandem Auto-Allo In Acute Myeloid Leukemia (AML) Patients In First Complete Remission (CR)  by Castagna, L. et al.
Poster Session II S275response. Genomic technologies can identify molecular subgroups
with distinct genomic signatures. We investigated the genomic
changes in patients with AML undergoing HCT using DNA mi-
croarrays. We analyzed 11 patients before HCT and at relapse after
HCT, 6 patients had a normal karyotype at diagnosis and 5 had ab-
normal karyotype with different types of aberrations. After high
resolution of whole genome DNA profiling analysis 5 of the 6 pa-
tients with normal karyotype showed genomic aberrations (GA) in
the form of gains and losses (5/5 gains/losses) in several regions of
different chromosomes with a median of 2 GA per case. The ab-
normal karyotype group, in addition to the cytogenetically detected
aberrations GA were present in 2 out of 5 patients (5/4 gains/los-
ses). Overall 64% of the patients had GA, not detected by conven-
tional cytogenetics. All FAB subtypes of AML showed GA, being
M5 and secondary AML both with more numerous GA (average:
12 and 17 GA respectively). At relapse 6 patients increased the
number of GA, (median of 7 GA per case), while 3 patients pre-
sented a reduced number of GA (median 2 GA per case). The re-
maining 2 patients showed no additional changes. Before
transplantation 16 chromosomes showed GA with a median of 3
GA per chromosome, average size of gains and losses were 1568
and 8046 kb respectively. At relapse 19 chromosomes had GA
with a median of 4 GA per chromosome, average size of gains
and losses were 697 and 8011 kb respectively. Chromosomes 11,
14 and 21 showed no GA at any time point. Our preliminary
data demonstrate that AML is a genomically heterogeneous disease
with a high incidence of small non recurrent DNA GA that can be
detected even in cases with normal karyotype. Cryptic genomic
changes are likely to play a role in relapse after allogeneic trans-
plantation.315
CLADRIBINE (2CDA) IS COMPARABLE TO FLUDARABINE IN A BUSULFAN-
BASED REDUCED- INTENSITY REGIMEN
Yakushijin, K., Fukuda, T., Asakura, Y., Kurosawa, S., Hiramoto, N.,
Tada, K., Nishinohara, M., Maeda, T., Hagiwara, A., Ueno, N.,
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Reduced-intensity stem cell transplantation (RIST) with a purine
analog most often involves fludarabine (Flu). The alternative drug,
2CdA, is rarely used partly because of a potential risk of renal
toxicity. We retrospectively reviewed the medical records of 282
patients (median age, 54 y; range, 21-68) with various hematolog-
ical malignancies who underwent RIST between 1999 and 2007
with a conditioning regimen that consisted of busulfan (po 8 mg/
kg or iv 6.4 mg/kg) in combination with either 2CdA (0.66 mg/
kg, n5 71, C-group) or Flu (180 mg/m2, n5 211, F-group). Se-
venty-four patients also received 2-4 Gy of TBI. The donor was re-
lated (BM 8, PB 177) in 185 patients, and unrelated in 97 (BM 79,
PB 1, CB 17). GVHD prophylaxis consisted of cyclosporine (CSP,
starting dose 3 mg/kg/day civ, target whole blood conc. 250-350
ng/ml, n5 232) or tacrolimus (starting dose 0.03 mg/kg/day civ,
target whole blood conc. 10-20 ng/ml, n5 50), with (n5 131) or
without (n5 151) MTX. Sixty-nine patients also received anti-hu-
man T- lymphocyte immunoglobulin (ATG, 5-10 mg/kg). Except
for the stem cell sources, there were no significant differences be-
tween the C- and F-groups. Acute renal failure (ARF) within 100
days was defined as there was a greater than two-fold rise in the se-
rum creatinine concentration compared to the baseline. The me-
dian follow-up in surviving patients was 1589 days (50-3291).
The 275 patients who survived more than 30 days (except for
one patient who died of relapse) all achieved neutrophil engraft-
ment in a median 13 days (range, 5-42 days). No significant differ-
ence was observed between C- and F-group with regard to OS
(59% vs 48% at 3 y, p5 0.20), relapse rate (42% vs 35% at 3 y,
p5 0.42), NRM (7% vs 6% on d100, 22% vs 32% at 3 y,
p5 0.15), or the cumulative incidences of ARF (34% vs 27% on
d 100, p5 0.26), grade II-IV acute GVHD (46% vs 47%,
p5 0.40), and extensive chronic GVHD (62% vs 54% at 3 y,
p5 0.21). Multivariate analyses showed that TBI [HR 2.96 (1.86-
4.72), p\0.001] for NRM, TBI [HR 1.75 (1.23-2.49), p5 0.002]and high-risk disease [HR 2.39 (1.62-3.55), p\0.001] for OS,
and TBI [HR 1.98 (1.25-3.14), p5 0.004] and CSP [HR 2.10
(1.06-4.17), p5 0.03] for ARF were significant factors for poor
outcomes. However, 2CdA was not significantly associated with
NRM, OS or ARF. Our study suggested that a relatively low
dose of 2CdA was tolerable and feasible as part of a reduced-
intensity regimen, and was not associated with any significant
nephrotoxicities.316
TANDEM AUTO-ALLO IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN
FIRST COMPLETE REMISSION (CR)
Castagna, L.1, Prebet, T.1, Fu¨rst, S.1, El-Cheikh, J.1, Charbonnier, A.1,
Faucher, C.1,Mohty,M.2, Chabannon, C.3, Vey, N.1, Blaise, D.1 1 Institut
Paoli Calmettes,Marseille, France; 2Hotel Dieu, Nantes, France; 3 Institut
Paoli Calmettes, Marseille, France
Background: High and intermediate risk AML can benefit from
allo-SCT in first CR. Reduced intensity conditionings (ALLO-
RIC) decreases toxicity. However there are now data in favour of
lower disease control as compared with standard CDT.We hypoth-
esized that if a better quality of remission could be achieved, the re-
lapse incidence could be lowered.
Patients and methods: From 2001 to 2008, 31 AML patients in
first CR received a tandem auto-allo program. At diagnosis, me-
dian number of WBC was 3  10e9/l (0.9-235), 13% of patients
have extramedullary localisations. 64% of patients were considered
at high-risk (cytogenetic, secondary disease or double inductions)
and 36% at intermediate risk. After reaching CR1, all but two pa-
tients received a consolidation course with high-dose cytarabine
(HD-ARAC, 24 g/m2 in 93%) CT, followed by autologous stem
cell harvest. HD melphalan (HD-PAM 140 mg/m2) was followed
by autologous stem cells reinfusion. Then, ALLO-RIC consisted
of fludarabine (90 mg/m2) plus (2 Gy) TBI (3 pts) or fludarabine
(150 mg/m2), busulfan over 2 days, and thymoglobuline (2.5 or
5 mg/kg). GVHD prophylaxis was CyA. 3 patients received also
mycofenolate mofetil. All donors, but one, were HLA identical
sibling. The median number of allo CD34+ cells was 6.1 
10e6/Kg. Prognostic scores (HCT-CI, PAM, EBMT) were retro-
spectively calculated for each patient. All pts have a performance
status$ 90%.
Results:Median fup from diagnosis and ALLO-RICwere 40 and 34
months, respectively. Median days between last CT and HD-PAM
was 51 (30-77) and between HD-PAM and ALLO-RIC was 69
(55-176). 5 pts relapsed for a 4 year CI of 15% (3-29). At last fup,
13 have died (relapse: 5; toxicity: 8). Grade II-IV aGVHD and
cGVHD CI were respectively 26% and 65% (extensive 84%).
GVHD was the cause of death in seven pts. Six pts (19%) reactived
CMV, and 1 pt did not survive to an interstitial pneumonitis. The
4-year overall survival (OS), relapse free survival (RFS), and 1-year
TRMwere 61% (43-76), 59% (41-75), and 16% (3-29), respectively.
In multivariate analysis, prognostic scores did not influence TRM
and OS.
Conclusions:This report showed that i) tandem auto-allo is feasible
in AML pts; ii) acute GVHD incidence is not increased; iii) prognos-
tic scores did not impact on TRM and survival; iv) TRM is low with
GVHDasmain cause of death; v) low relapse rate is documented and
invites further development.317
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Introduction: Allogeneic Stem Cell Transplantation (Al-SCT) re-
mains an option for patients with advanced Chronic Lymphocytic
Leukemia (CLL) with high risk features.
